Drug Maker Agrees to $32 Million Resolution of AKS Allegations
- September 18, 2026
- Written by AHLA Legal Staff
Pharmaceutical manufacturer Dompé U.S. Inc. has agreed to pay $32 million to resolve allegations that it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug Oxervate in violation of the Anti-Kickback Statute, the Department of Justice announced September 10.
As part of the settlement, Dompé admitted that, around the time of Oxervate’s 2018 launch in the United States, two foundations opened funds that paid co-pays for Oxervate, and Dompé made contributions to those foundations. Dompé also solicited patient assistance foundation data directly from the foundations and from the specialty pharmacy that provided hub services to Dompé U.S. patients.
Dompé is the U.S. subsidiary of Dompé farmaceutici S.p.A., which self-disclosed the conduct to the United States.
The settlement resolves allegations only and there has been no determination of liability.